Home > Newsletters > Generic Line > FTC: Patent Deals Need Not Involve Overt Payments to Be Anticompetitive
Aug. 29, 2012 | Vol. 29 No. 17
FTC: Patent Deals Need Not Involve Overt Payments to Be Anticompetitive
Patent settlements that involve a branded company’s commitment to not launch an authorized generic (AG) in competition with a generic company (no-AG agreements) are “without a doubt” anticompetitive pay-for-delay deals even though no cash payments are involved, the FTC says in an amicus brief.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.